Abstract

The research proposals in this SPORE encompass a broad range of activities, including studies with cell lines, animal models, and clinical trials. These studies will generate different types of data. Properly designing and analyzing such a wide variety of studies will require a variety of statistical and bioinformatics techniques Data and information must flow smoothly between projects. Data quality and integrity must be ensured by using data audit and backup procedures. Also needed is an efficient interface between the computational biology and data storage facilities provided by the SPORE Core C (Pathology and Data Management Core), particularly forthe large amounts of microarray and proteomics expression profiling information. To meet these needs, the Biostatistics and Bioinformatics Core brings together several biostatisticians, bioinformaticians and analysts with expertise in a variety of statistical and bioinformatics disciplines. Placing these individuals within the Biostatistics and Bioinformatics Core (rather than in the individual Projects) strengthens the ability of the Projects to interact effectively. This resource also has the flexibility to match personnel to the evolving biostatistics and bioinformatics needs of the SPORE projects. The Biostatistics and Bioinformatics Core will provide expertise in study design and data analysis to all Projects and Cores.
The specific aims of the Biostatistics and Bioinformatics Core are to:
The specific aims of the Biostatistics and Bioinformatics Core are to: 1. Provide guidance in the design and conduct of clinical trials and other experiments arising from the ongoing research of the SPORE. 2. Provide the innovative and tailored statistical modeling, simulation techniques, and data analyses needed by the Projects, Developmental Research and Career Development Projects, and other Cores to achieve their specific aims. 3. Ensure that the results of all Projects are based on well-designed experiments and are appropriately interpreted.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA091846-11
Application #
8230259
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (O1))
Project Start
2011-09-01
Project End
2017-08-31
Budget Start
2012-09-19
Budget End
2012-08-31
Support Year
11
Fiscal Year
2012
Total Cost
$203,200
Indirect Cost
$66,291

  Institution

Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030

  Publications

Duplisea, Jonathan J; Mokkapati, Sharada; Plote, Devin et al. (2018) The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J Urol :
Choi, Woonyoung; McConkey, David (2018) Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas D Eur Urol 73:e104-e105
Zhang, Miao; Adeniran, Adebowale J; Vikram, Raghunandan et al. (2018) Carcinoma of the urethra. Hum Pathol 72:35-44
Wang, Gang; Xiao, Li; Zhang, Miao et al. (2018) Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol 79:57-65
Zhang, Shizhen; Wang, Yan; Bondaruk, Jolanta et al. (2018) Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test. Eur Urol Focus :
Jazzar, Usama; Yong, Shan; Klaassen, Zachary et al. (2018) Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States. Cancer 124:3127-3135
Westhoff, Ellen; Wu, Xifeng; Kiemeney, Lambertus A et al. (2018) Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. Int J Cancer 142:1797-1804
Shore, Neal D; Boorjian, Stephen A; Canter, Daniel J et al. (2017) Intravesical rAd-IFN?/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol 35:3410-3416
Lin, Moubin; Zhang, Liren; Hildebrandt, Michelle A T et al. (2017) Common, germline genetic variations in the novel tumor suppressor BAP1 and risk of developing different types of cancer. Oncotarget 8:74936-74946
Metcalfe, Michael J; Ferguson, James E; Li, Roger et al. (2017) Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus 3:577-583

Showing the most recent 10 out of 247 publications